SIETES :: 92825 citas

Resultados de la búsqueda por BIOTECNOLOGÍA REFINAR BÚSQUEDA

1.

Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol 2019:10 de mayo. [Ref.ID 103131]

2.

Anónimo. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. U.S. Food and Drug Administration 2019:9 de abril. [Ref.ID 103084]

3.

Jones G. Orphan drugs market to soar to $224bn by 2024. Cell and gene therapies to fuel growth. PMLiVE 2019:25 de abril. [Ref.ID 103080]

4.

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

5.

Pinto T. Los nuevos anticoagulantes obligan a las farmacéuticas a pagar cientos de millones para evitar juicios . eldiario.es 2019:31 de marzo. [Ref.ID 103065]

6.

Silverman E. STAT Plus: AbbVie is sued for using Humira patent deals to block competition in the U.S.. STAT Daily Recap 2019:20 de marzo. [Ref.ID 103062]

7.

Anónimo. Ocrélizumab et sclérose en plaques. Prescrire 2018;38:890-2. [Ref.ID 102904]

8.

Xu C, Chen Y-P, Du X-J, Liu J-Q, Huang C-L, Chen L, Zhou G-Q, Li W-F, Mao Y-P, Hsu C, Liu Q, Lin A-H, Tang L-L, Sun Y, Ma J. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 2018;363:8 de noviembre. [Ref.ID 102847]

9.

Moore TJ, Hanzhe Z, Anderson G, Alexander C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med 2018:24 de septiembre. [Ref.ID 102831]

10.

Sinha MS, Curfman GD, Carrier MA. Antitrust, market exclusivity, and transparency in the pharmaceutical industry. JAMA 2018;319:12 de junio. [Ref.ID 102779]

11.

Anónimo. Atézolizumab et cancer bronchique métastasté ou inopérable. Prescrire 2018;38:503-4. [Ref.ID 102758]

12.

Anónimo. Inotuzumab ozogamicine et leucémie aiguë lymphoblastique chez les adultes. Prescrire 2018;38:494-9. [Ref.ID 102757]

13.

Desjardins A, Gromeier M, Herndon II JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 2018;379:12 de juliol. [Ref.ID 102734]

14.

Anónimo. Bill And Melinda Gates build A “biotech-within-a-charity”. DIA Daily 2018:1. [Ref.ID 102662]

15.

Anónimo. Alectinib et cancers bronchiques ALK-positifs. Prescrire 2018;38:337-9. [Ref.ID 102653]

16.

Maya Y, Ota M. Drug-induced localised scleroderma. BMJ 2018;360:12 de abril. [Ref.ID 102643]

17.

Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;378:24 de mayo. [Ref.ID 102636]

18.

Tsourdi E, Rachner TD, Hofbauer LC. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102629]

19.

Lewis JR, Schousboe JT, Prince RL. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102628]

20.

Song GG, Lee YH. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102627]